BioTech

Lilly To Acquire Centessa; Upfront Consideration Represents Equity Value Of Approx. $6.3 Bln

March 31, 2026 — 07:02 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Eli Lilly and Company (LLY) and Centessa Pharmaceuticals plc (CNTA) announced a definitive agreement for Lilly to acquire Centessa. Lilly will acquire all of the issued and to be issued share capital of Centessa for $38.00 in cash per share plus one non-transferrable CVR that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of milestones, for total potential aggregate per share consideration of up to $47.00. The upfront cash consideration represents an aggregate equity value of approximately $6.3 billion. The CVR represents an additional potential aggregate equity value of approximately $1.5 billion.

"Centessa is at the forefront of orexin science, and we've built a potential best-in-class portfolio of OX2R agonists with a level of depth and breadth that could help redefine what's possible in neuroscience," said Mario Alberto Accardi, CEO of Centessa.

In pre-market trading on NasdaqGS, Centessa shares are up 46.96 percent to $40.53.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Lilly To Acquire Centessa; Upfront Consideration Represents Equity Value Of Approx. $6.3 Bln

Tags

Latest Articles